Treatment of postpartum arterial hypertension with losartan in severe preeclampsia
Main Article Content
Keywords
Postpartum Period, High-Risk, Pregnancy, Pre-Eclampsia, Losartan, Hypertension
Abstract
Background: Postpartum hypertension increases the risk of acute and chronic complications in patients with preeclampsia. Losartan may be a useful drug alternative.
Objective: To determine the results of treatment of postpartum hypertension with losartan in patients with severe preeclampsia.
Method: Uncontrolled clinical trial in 49 patients with severe preeclampsia. After gestational interruption, two groups were formed: group A (n = 24) received the standard antihypertensive regimen (methyldopa 1500 mg/day, hydralazine 200 mg/ day, metoprolol 200 mg/day), and group B (n = 25) the same treatment plus losartan 100 mg/day for 90 days. In both groups, methyldopa, hydralazine and metoprolol was reduced or suspended in that order; in group B, losartan was maintained with the same or half the dose without suspending it. Baseline and final values (day 90) of systolic (SBP) and diastolic blood pressure (DBP) were compared. Descriptive and inferential statistics were applied (Student’s t test for paired samples, Mann-Whitney U test, Wilcoxon’s signed rank test). It was significant a p < 0.05.
Results: Group A: baseline SBP 135.46 ± 13.88 vs. final 109.76 ± 10.54 mmHg (p < 0.001) and basal DBP 85.71 ± 10.17 vs. final 72.14 ± 10.55 mmHg (p < 0.001). Group B: basal SBP 135.84 ± 14.39 vs. final 110.68 ± 9.79 mmHg (p < 0.001) and baseline DBP 83.08 ± 9.58 vs. final 72.61 ± 9.16 mmHg (p < 0.001).
Conclusions: Both treatments similarly reduced SBP and DBP at the 90-day measurement.
References
1. Andrus SS, Wolfson AB. Postpartum preeclampsia occurring after resolution of antepartum preeclampsia. J Emerg Med. 2010;38(2):168-70. doi:10.1016/j.jemermed.2008.04.039
2. American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. Washington:ACOG;2013.
3. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P;on behalf of the Canadian Hypertensive Disorders of Pregnancy working group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertension. 2014;4:105-45. doi:10.1016/j.preghy.2014.01.003
4. Guía de práctica clínica de prevención, diagnóstico y tratamiento de la preeclampsia en el segundo y tercer nivel de atención. México:Secretaría de Salud;2017. (Consultado el 23 agosto de 2019.) Disponible en:http://www.cenetec-difusion.com/CMGPC/S-020-08/ER.pdf
5. Pauli JM, Reptke JT. Preeclampsia, short-term and long-term implications. Obstet Gynecol Clin N Am. 2015;42:299-313. doi:10.1016/j.ogc.2015.01.007
6. Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of pre-eclampsia. Curr Opin Nephrol Hypertens. 2015;24(2):131-8. doi:10.1097/MNH.0000000000000 105
7. Rylander R. Pre-eclampsia during pregnancy and cardiovascular disease later in life:the case for a risk group. Arch Gynecol Obstet. 2015;292:51921. doi:10.1007/s00404-015-3676-3
8. OruetaSánchez R, LópezGil MJ. Manejo de fármacos durante el embarazo. Inf Ter Sist Nac Salud. 2011;35:107-13. (Consultado el 23 agosto de 2019.) Disponible en:https://www.mscbs.gob.es/biblioPublic/publicaciones/recursos_propios/infMedic/docs/EmbarazoVol35n4.pdf
9. Drugs.com. Losartan. (Actualizado el 5 de diciembre de 2018;consultado el 23 de agosto de 2019.) Disponible en:https://www.drugs.com/losartan.html
10. Drugs.com. Losartan pregnancy and breastfeeding warnings. (Actualizado el 5 de diciembre de 2018;consultado el 23 de agosto de 2019.) Disponible en:https://www.drugs.com/pregnancy/losartan.html
11. Manten GT, Sikkema MJ, Voorbij HA, Visser GH, Bruinse HW, Franx A. Risk factors for cardiovascular disease in women with a history of pregnancy complicated by preeclampsia or intrauterine growth restriction. Hypertens Pregnancy. 2007;26(1):39-50. doi:10.1080/10641950 601146574
12. Berends AL, de Groot CJM, Sijbrands EJ, Sie MPS, Benneheij SH, Pal R, et al. Shared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. Hypertension. 2008;51(4):1034-41. (Consultado el 23 de agosto de 2019.) Disponible en:https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.107.101873
13. Edlow AG, Srinivas SK, Elovitz MA. Investigating the risk of hypertension shortly after pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2009;200(5):e60-2. doi:10.1016/j.ajog.2008.10.012
14. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338:1128-37. doi:10.1056/NEJM199804163381607
15. Phillips SJ, Whisnant JP. Hypertension and stroke. En:Laragh JH, Brenner BM, editores. Hypertension:pathophysiology, diagnosis, and management. 2nd ed. New York:Raven Press;1995. 465-78.
16. Makkonen N, Harju M, Kirkinen P. Postpartum recovery after severe pre-eclampsia and HELLP-syndrome. J Perinat Med. 1996;24:641-9.
17. Remuzzi G, Ruggenenti P. Prevention and treatment of pregnancy associated hypertension:what have we learned in the last 10 years?Am J Kidney Dis. 1991;18:285-305. doi:10.1016/S0272-6386(12)80087-4
18. Chua S, Redman CW. Prognosis for pre-eclampsia complicated by 5 g or more of proteinuria in 24 hours. Eur J Obstet Gynecol Reprod Biol. 1992;43(1):912. doi:10.1016/0028-2243(92)90236-r
19. Stepan H, Nordmeyer AK, Faber R. Proteinuria in hypertensive pregnancy diseases is associated with a longer persistence of hypertension postpartum. J Hum Hypertens. 2006;20(2):125-8. doi:10.1038/sj.jhh.1001952
20. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med. 2008;359:800-9. doi:10.1056/NEJMoa0706790
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.